The RPL estimation results in the main effect with interaction (Model 2) (Only significant variables). by Keiko Aoki (10535562)

Risk of bias assessment using the Cochrane risk of bias assessment tool (RoB 2). by Alain Nahaskida (21474469)

Publication bias using Egger’s test. by Muluneh Assefa (12029676)

Subjects:

Risk of bias assessment and reasons for exclusion. by Min Sun (115484)

Assessment of risk of bias of included studies. by Serena Isley (17833672)

Subjects:

Risk of bias of included studies for recurrence. by ChenXin Zhang (20396408)

Risk of bias summary: authors’ judgments about each item of the risk of bias assessment for every included study. by Yuhan Wen (16424447)

Bias original and unbiased shifted AE signals. by Zazilah May (9306002)

Risk of bias graph. by Manuel E. Becerra-Bizarrón (22566742)

Significantly Boosted Th2-Selective Activity of NKT Cell Agonist Enabled by Sulfonamide Hydrogen-Bond Design by Yu Wen (303123)

Subjects: “…sulfonamide derivation based…”

Significantly Boosted Th2-Selective Activity of NKT Cell Agonist Enabled by Sulfonamide Hydrogen-Bond Design by Yu Wen (303123)

Subjects: “…sulfonamide derivation based…”

Detailed risk of bias assessment. by Sommy C. Ugwu (19832253)

Model bias. by Karly McMullen (17841502)

A: Risk of bias graph; B: Risk of bias summary. by Ruo-Yang Li (13955250)

“…</p><p>Conclusion</p><p>Multi-drug therapy based on eszopiclone can effectively improve the sleep quality of patients with insomnia after stroke, and ESZ+SDOL has significant efficacy and safety. …”

Risk of bias summary. by Chao Gao (154531)

“…However, in LVEF(left- ventricular ejection fraction)[WMD = 0.32mL 95%CI (-1.83, 2.46), P = 0.699, I² = 0%], LVEDV(left ventricular end-diastolic volume)[WMD = 0.91 ml 95%CI (-1.83, 2.46), P = 0.995, I² = 0%] and SBP(systolic blood pressure)[WMD = 1.85mmHg 95%CI (-0.23, 3.93),P = 0.266, I² = 18.2%], there was no significant difference between HIIT and MICT.</p><p>Conclusion</p><p>Based on the findings of this systematic review, HIIT demonstrates superior efficacy compared to MICT in enhancing PeakVO₂, PHR, 6MWT and DBP. …”

Results from the risk of bias assessment of outcomes included in the vote-counting analysis. by Siv Linnerud (17618923)

Risk-of-bias graph. by Shuai-yang Huang (13154858)

Risk assessment of bias in included studies. by Ruiqi Wu (12046253)

Subjects:

The GmNN1/FT2a-GmNFYA-C-GmENOD40 module regulates soybean nodulation. by Xinxin Li (281237)

Risk of bias assessment of included RCTs. by Catherine Arundel (3558773)